Back to School: How biopharma can reboot drug development. Access exclusive analysis here

VBL's VB-111 misses in Phase III for glioblastoma

Vascular Biogenics Ltd. (NASDAQ:VBLT) reported that ofranergene obadenovec (VB-111) missed the primary endpoint of improving overall survival (OS) in the Phase III GLOBE trial to treat recurrent

Read the full 273 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE